Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Mller DM, et al
Easy measuring: At 0.333 mg/mL, 1 unit = 0.01 mL 3.33 mcg on a U-100 insulin syringe
Legal Status CJC-1295 is currently classified as a research chemical with no formally recognized use
In-vivo references cite for bone healing studies about 140 microg per injection over 10 days
Dual-pathway signaling CJC-1295 targets GHRH receptors Ipamorelin targets GHS-R receptors Broader systemic signaling profile Often discussed in recovery and sleep contexts More generalized effects Broader tissue interaction Less concentrated GH spikes More gradual GH pulse curve Commonly associated with systemic support Where Sermorelin fits Sermorelin is generally considered a milder and shorter-acting GHRH analogue compared to Tesamorelin
While patients living with chronic life-threatening conditions like Type 2 diabetes may accept these risks, people using GLP-1 drugs for less life-threatening and severe purposes like obesity may be less forgiving if the side effects outweigh the perceived benefits
